Literature DB >> 16797200

Immunogenicity and structural characterisation of an in vitro folded meningococcal siderophore receptor (FrpB, FetA).

Jeroen Kortekaas1, Shirley A Müller, Philippe Ringler, Marco Gregorini, Vincent E Weynants, Lucy Rutten, Martine P Bos, Jan Tommassen.   

Abstract

The iron-limitation-inducible protein FrpB of Neisseria meningitidis is an outer-membrane-localized siderophore receptor. Because of its abundance and its capacity to elicit bactericidal antibodies, it is considered a vaccine candidate. Bactericidal antibodies against FrpB are, however, type-specific. Hence, an FrpB-based vaccine should comprise several FrpB variants to be capable of providing broad protection. To facilitate the development of a meningococcal subunit vaccine, we have established a procedure to obtain large quantities of the protein in a native-like conformation. The protein was expressed without its signal sequence in Escherichia coli, where it accumulated in inclusion bodies. After in vitro folding, the protein was biochemically, biophysically and biologically characterised. Our results show that in vitro folded FrpB assembles into oligomers, presumably dimers, and that it induces high levels of bactericidal antibodies in laboratory animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797200     DOI: 10.1016/j.micinf.2006.04.011

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  12 in total

1.  Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis.

Authors:  Muhammad Saleem; Stephen M Prince; Hema Patel; Hannah Chan; Ian M Feavers; Jeremy P Derrick
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-01-27

2.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

3.  Deletion of fetA gene sequences in serogroup B and C Neisseria meningitidis isolates.

Authors:  Jane W Marsh; Mary M O'Leary; Kathleen A Shutt; Lee H Harrison
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

4.  Functioning of outer membrane protein assembly factor Omp85 requires a single POTRA domain.

Authors:  Martine P Bos; Viviane Robert; Jan Tommassen
Journal:  EMBO Rep       Date:  2007-11-09       Impact factor: 8.807

5.  Helicobacter pylori HP0876 is dispensable for heme-iron acquisition but attenuates bacterial adherence to gastric epithelial cells.

Authors:  Tao Liu; Yun Shi; Xiao-fei Liu; Ying Guo; Xu-hu Mao; Che Tan; Yuan Zhuang; Liu-sheng Peng; Jin-yu Zhang; Quan-ming Zou
Journal:  Curr Microbiol       Date:  2012-06-28       Impact factor: 2.188

Review 6.  Subversion of nutritional immunity by the pathogenic Neisseriae.

Authors:  Cynthia Nau Cornelissen
Journal:  Pathog Dis       Date:  2018-02-01       Impact factor: 3.166

7.  Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

Authors:  Vincent E Weynants; Christiane M Feron; Karine K Goraj; Martine P Bos; Philippe A Denoël; Vincent G Verlant; Jan Tommassen; Ian R A Peak; Ralph C Judd; Michael P Jennings; Jan T Poolman
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

8.  An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity.

Authors:  Gunnstein Norheim; Holly Sanders; Jardar W Mellesdal; Idunn Sundfør; Hannah Chan; Carina Brehony; Caroline Vipond; Chris Dold; Rory Care; Muhammad Saleem; Martin C J Maiden; Jeremy P Derrick; Ian Feavers; Andrew J Pollard
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

9.  A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.

Authors:  L Marsay; C Dold; C A Green; C S Rollier; G Norheim; M Sadarangani; M Shanyinde; C Brehony; A J Thompson; H Sanders; H Chan; K Haworth; J P Derrick; I M Feavers; M C Maiden; A J Pollard
Journal:  J Infect       Date:  2015-05-15       Impact factor: 6.072

10.  Evaluation of truncated NhhA protein as a candidate meningococcal vaccine antigen.

Authors:  Ian R Peak; Yogitha N Srikhanta; Vincent E Weynants; Christiane Feron; Jan T Poolman; Michael P Jennings
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.